ORGANIZING COMMITTEE

Pr Jean-Louis Merlin, Nancy, France
Dr Alexandre Harlé, Nancy, France
Pr Nikolas von Bubnoff, Freiburg, Germany
Dr Florence Schaffner, Strasbourg, France

ACKNOWLEDGEMENTS

ORGANIZATION

Com&Co - Etienne Jarry
15, Bd Grawitz - 13016 Marseille, France
Tel.: +33 (0)4 91 09 70 53 - Fax: +33 (0)4 96 15 33 08
Email: ejarry@comnco.com - www.comnco.com

SCIENTIFIC COMMITTEE / FACULTY

Anna Babayan, Hamburg, Germany
Fay Betsou, Luxembourg
Romain Boidot, Dijon, France
Florian Clatot, Rouen, France
Christine Clavel, Reims, France
Ralph Fritsch, Freiburg, Germany
Anne Gégout-Petit, Nancy, France
Alexandre Harlé, Nancy, France
Jens Höppner, Freiburg, Germany
Katarina Jahn, Basel, Switzerland
Philippe Jonveaux, Nancy, France
Pierre Laurent-Puig, Paris, France
Jean-Louis Merlin, Nancy, France
Irina Nazarenko, Freiburg, Germany
Pierre Oudet, Strasbourg, France
Nick Papadopoulos, Baltimore, USA
Erwan Pencrêac’h, Strasbourg, France
Jean-Yves Pierga, Paris, France
Jean-Luc Prétet, Besançon, France
Florence Schaffner, Strasbourg, France
Florian Scherer, Freiburg, Germany
Giulia Siravegna, Torino, Italy
Dana Tsui, New York, USA
Martin van Royen, Rotterdam, The Netherlands
Jean-Michel Vignaud, Nancy, France
Nikolas von Bubnoff, Freiburg, Germany
MONDAY, SEPTEMBER 25TH, 2017

08.15 Welcoming introduction

08.30 SESSION 1
DIAGNOSTIC, SCREENING, MONITORING
Chairs: Nikolas von Bubnoff (Freiburg, Germany) & Jean-Louis Merlin (Nancy, France)

08.30 ctDNA for cancer detection and management: ready for prime time? Dana Tsui (New York, USA)

09.00 CTC and ctDNA in breast cancer: prognosis marker or molecular diagnostic. Jean-Yves Pierga (Paris, France)

09.30 Colon and lung cancer role of liquid biopsy. Pierre Laurent-Puig (Paris, France)

10.00 Short communications

10.00 Circulating tumor DNA is a predictor for response to treatment in BRAF V600E mutant malignant melanoma. Jan Braune (Freiburg, Germany)

10.10 Rapid and clinically relevant detection of the spectrum of ALK fusion and mutations in non-invasive liquid biopsy ctDNA from patients with lung cancer. Antoinette Lemoine (Villejuif, France)

10.20 CTCs in patients with esophageal adenocarcinoma at diagnosis, after neoadjuvant treatment and after surgery (ESO-CTC trial). Jasmina Kuvendjiska (Freiburg, Germany)

10.30 Coffee break & poster session

11.00 SESSION 2
RESISTANCE TO TREATMENT, CLONAL EVOLUTION
Chairs: Alexandre Harlé (Nancy, France) & Ralph Fritsch (Freiburg, Germany)

11.00 Monitoring clonal evolution and resistance to targeted agents in the blood and other body fluids of cancer patients. Giulia Siravegna (Torino, Italy)

11.20 Capturing clonal evolution and tumor heterogeneity in lymphoma by circulating tumor DNA profiling. Florian Scherer (Freiburg, Germany)

11.40 ctDNA and breast cancer resistance to endocrine therapy. Florian Clatot (Rouen, France)

12.00 Short communications

12.00 Study of spatial and temporal tumor heterogeneity using whole exome sequencing on ctDNA in neuroblastoma. Mathieu Chichard (Paris, France)

12.10 Identification of rare mutations and DNA methylation patterns in cell-free DNA and their impact on personalized cancer treatment using multiplexed Enhanced-ice-COLD-PCR. Jörg Tost (Fontenay-aux-Roses, France)

12.30 Lunch break & poster session

14.00 SESSION 3
LIQUID BIOPSY ANALYTICS
Chairs: Jean-Michel Vignaud (Nancy, France) & Jens Höppner (Freiburg, Germany)

14.00 Liquid biopsy: CTCs versus circulating nucleic acids. Anna Babayan (Hamburg, Germany)

14.30 Modeling ctDNA dynamics for detecting targeted therapy resistance. Anne Gégout-Petit (Nancy, France)

14.50 Modelling tumor evolution from single-cell sequencing data. Katarina Jahn (Basel, Switzerland)

15.10 Short communications

15.10 Detection of circulating KRAS mutations in patients with pancreatic cancer: a single center experience. Saskia Hussung (Freiburg, Germany)

15.20 Establishing barcoding and target capturing for NGS based ctDNA panel sequencing of NSCLC-patients stages I-III. Silvia Waldeck (Freiburg, Germany)

15.30 Coffee break & poster session

16.00 SESSION 4
CIRCULATING BIOMARKERS
Chairs: Erwan Pencreac’h (Strasbourg, France) & Irina Nazarenko (Freiburg, Germany)

16.00 The use of extracellular vesicles as prostate cancer biomarker treasure chests. Martin van Royen (Rotterdam, The Netherlands)

16.30 Different types of extracellular vesicles and their application in cancer diagnostics. Irina Nazarenko (Freiburg, Germany)

16.50 Quality assurance of liquid biopsy in research. Fay Betsou (Luxembourg)

17.10 Short communications

17.10 Tumor derived exosomes as potential metastasis biomarker. Jessica Gobbo (Dijon, France)

17.20 Diagnostic potential of micro RNAs expression profiles in serum and urine of breast and gynecologic cancer patients. Andrea Ritter (Freiburg, Germany)

17.30 KEYNOTE LECTURES

17.30 Detection of cancer in bodily fluids. Nick Papadopoulos (Baltimore, USA)

18.00 Liquid biopsy, CTC and circulating nucleic acids: making the buzz or doing the job? Nikolas von Bubnoff (Freiburg, Germany) & Jean-Louis Merlin (Nancy, France)

18.15 Short communication & poster prizes

18.30 Concluding remarks

18.50 Meeting closure